RxDoctor Payments Data

David Dunhill, MD

Internal Medicine · Fort Lauderdale, FLNPI 1336465574

Payments from drug & device makers

$2,140in general payments, 2019–2025

Across 121 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$574
  • Pfizer$344
  • AbbVie$200
  • Lilly USA, LLC$147
  • Amgen$140
  • Boehringer Ingelheim$98
  • plus $638 from 18 others

What the payments were for

  • Food & beverage$2,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,140 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$175,358
Medicare patients
519
Services billed
1,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$104,552
JardianceEmpagliflozin88$97,839
EliquisApixaban81$84,585
XareltoRivaroxaban54$54,455
MounjaroTirzepatide41$48,004
TrulicityDulaglutide19$38,421
Breo ElliptaFluticasone/Vilanterol42$24,747
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,251
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$10,969
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)13$9,388
Atorvastatin Calcium826$7,137
EntrestoSacubitril/Valsartan11$6,952
Rosuvastatin Calcium528$6,245
FarxigaDapagliflozin Propanediol11$5,401
SynthroidLevothyroxine Sodium73$3,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$574$104,55281 claims
Boehringer IngelheimJardiance$98$97,83988 claims
Lilly USA, LLCMounjaro, Trulicity$147$86,42560 claims
PfizerEliquis$344$84,58581 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$54$56,96684 claims
Johnson & JohnsonXarelto$57$54,45554 claims
NovartisEntresto$14$6,95211 claims
AstraZenecaFarxiga$20$5,40111 claims
AbbVieSynthroid$200$3,98773 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →